Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
What each said, in their own words
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the consultation and would like to emphasise the following: 1. Ensure access: • HTA: RCE encourages the harmonisation of HTA processes and to ensure the concept of joint clinical assessments, to avoid the duplication of clinical assessments at national level, as foreseen by the draft HTA regulation.
ERS appreciates the opportunity to contribute to this roadmap on the revision of the General Pharmaceutical legislation (namely Directive 2001/83/EC1 and Regulation (EC) No 726/20042). Join the dots: Legislation must foster medical advancement not hamper it.
Answer to the request for feedback on the revision of the EU general pharmaceutical legislation The European Respiratory Society, (ERS) is one of the leading medical organisations in the respiratory field, with a growing membership spanning over 160 countries.
Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the EU efforts towards the creation of a European Health Data Space (EHDS). Rare cancers are a neglected area deserving dedicated attention as 24% of all new cancer diagnoses, including all paediatric cancers, are rare.
The European Respiratory Society appreciates the opportunity to input to the proposal on the European Health Data Space for better healthcare, research and policy-making. The COVID-19 pandemic has clearly shown the benefits that better sharing and use of health data could bring to healthcare in the EU.
The European Respiratory Society appreciates the opportunity to give feedback to the proposal on the European Health Data Space (EHDS) for better healthcare, research and policy-making. The COVID-19 pandemic has shown the need of electronic health data for the development of policy response to health emergencies, better preparedness of healthcare services and for fostering research and innovation.
Rare Cancers Europe (RCE), a 39 partner strong multi-stakeholder partnership, welcomes the EU efforts to assessing solutions to improve the legislative environment on medicines for rare diseases, including rare cancers. With more than 20% of all new cancer cases being rare, including all paediatric cancers, rare cancers belong to both cancers and rare diseases.
The European respiratory Society (ERS) is an international organisation that brings together physicians, healthcare professionals, scientists and other experts working in respiratory medicine. It is one of the leading medical organisations in the respiratory field, with a growing membership representing over 160 countries worldwide.
Take this comparison with you
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.